Although the present study has been focused on the clinical response to sorafenib, the interesting results obtained here suggest that further investigations are required to elucidate whether similar relationship is also valid for other TKIs, such as novel and promising MET inhibitors tivantinib and cabozantinib, currently under clinical evaluation for the treatment of HCC [9]. The gene discussed is MET; the disease is hepatocellular carcinoma.